Sotatercept for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease: Efficacy and Safety Insights
Journal of Clinical Medicine · 22.07.2025 · 14 (15) · 5177
DOI: 10.3390/jcm14155177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 22.07.2025. Verfasst von Chebly Dagher und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Connecticut, Farmington, CT 06269, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Sotatercept has demonstrated efficacy in pulmonary arterial hypertension (PAH), but its use has not been studied in patients with Group 3 pulmonary hypertension (PH). Additionally, patients with connective tissue disease-associated PAH (CTD-PAH) were underrepresented in the STELLAR trial. Given the limited treatment options for pulmonary hypertension in patients with interstitial lung disease (PH-ILD), this study aimed to evaluate the use of sotatercept in CTD-PAH patients with concomitant ILD.
Methods
Eligible patients (n = 7) had a confirmed diagnosis of CTD-PAH with concomitant ILD. The patients were already receiving background PAH therapy. Baseline hemodynamic and clinical measurements were reassessed after 24 weeks of sotatercept therapy. The variables assessed included six-minute walk distance (6MWD), pulmonary vascular resistance (PVR), echocardiographic right ventricular systolic pressure (eRVSP), N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, World Health Organization (WHO) functional class, and supplemental oxygen requirements.
Results
The study included seven patients with a mean age of 57 years (range: 39–73 years). After 24 weeks, the mean 6MWT distance increased from 211 m to 348 m (p < 0.01). Mean PVR decreased from 7.77 WU at baseline to 4.53 WU (p < 0.01). Mean eRVSP decreased from 79.43 mmHg to 54.14 mmHg (p < 0.01). NT-proBNP decreased from 3056.86 pg/mL to 1404.29 pg/mL (p < 0.01). The WHO functional class and supplemental oxygen requirements improved in all patients.
Conclusions
Sotatercept was tolerated in patients with CTD-PAH and ILD, with no evidence of adverse respiratory effects. When added to foundational PAH therapy, sotatercept resulted in significant improvements across multiple parameters. These findings suggest that sotatercept may be a promising therapeutic option as an adjunctive treatment in this patient population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Connecticut, Farmington, CT 06269, USA.
- Division of Pulmonary, Critical Care and Sleep, Hartford Hospital, Hartford, CT 06106, USA.
- Division of Pulmonary, Critical Care and Sleep, School of Medicine, University of Connecticut, Farmington, CT 06030, USA.
- Division of Pulmonary, Sleep and Critical Care Medicine, Tufts Medical Center, Boston, MA 02111, USA.
ORCID-Profile: Chebly Dagher
Zitieren
APA
Dagher, C., Akiki, M., Swanson, K., Carollo, B., Fiscus, G., Farber, H. W., & Parikh, R. (2025). Sotatercept for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease: Efficacy and Safety Insights. Journal of Clinical Medicine, 14(15), 5177. https://doi.org/10.3390/jcm14155177
Vancouver
Dagher C, Akiki M, Swanson K, Carollo B, Fiscus G, Farber HW, et al. Sotatercept for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease: Efficacy and Safety Insights. Journal of Clinical Medicine. 2025;14(15):5177. doi:10.3390/jcm14155177
BibTeX
@article{Dagher2025,
author = {Dagher, Chebly and Akiki, Maria and Swanson, Kristin and Carollo, Brett and Fiscus, Garett and Farber, Harrison W and Parikh, Raj},
title = {Sotatercept for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease: Efficacy and Safety Insights},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {15},
pages = {5177},
doi = {10.3390/jcm14155177}
}
EUVIMED